Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Sergio Frustaci"'
Autor:
Maurizio Mongiat, Stefano Marastoni, Giovanni Ligresti, Erica Lorenzon, Monica Schiappacassi, Roberto Perris, Sergio Frustaci, Alfonso Colombatti
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 4, Pp 294-304 (2010)
We have recently reported that elastin microfibril interface located protein 2 (EMILIN2), an extracellular matrix (ECM) glycoprotein, triggers cell death through a direct binding to death receptors. EMILIN2 thus influences cell viability through a me
Externí odkaz:
https://doaj.org/article/ba5c7ce1293e45a5bc4e1c61634aae71
Autor:
Armando Santoro, Antonella Romanini, Alberto Rosso, Sergio Frustaci, Alessandro Comandone, Gaetano Apice, Domenico De Toma, Luigi Dogliotti, Rita Lionetto, Carla Dani, Paolo Bruzzi, Marco Piolini, Paola Bergnolo, Claudio Verusio
Publikováno v:
Sarcoma, Vol 3, Iss 3-4, Pp 177-181 (1999)
Purpose. The prognosis of advanced soft tissue sarcoma is poor, only a few drugs showing some activity with response rates around 15– 25%. Consequently drug development seems mandatory to improve treatment outcome. Following previous favourable
Externí odkaz:
https://doaj.org/article/d6b2af2f35254690a34379f86784e7de
Phase I trial of docetaxel, oxaliplatin, and capecitabine (DOC) in untreated gastric cancer patients
Autor:
Giuseppe Toffoli, Angela Buonadonna, Sergio Frustaci, Gianna Tabaro, Salvatore Tumolo, Giovanni Lo Re, Elisa Turchet, Elena Torrisi, Gianmaria Miolo, Giuseppe Corona
Publikováno v:
International Journal of Clinical Oncology. 18:510-516
A combination of docetaxel (D), oxaliplatin (O), and capecitabine (C) (DOC) was studied in this dose-escalation phase Ib trial in patients with untreated advanced gastric cancer. Dose-limiting toxicity (DLT) included any grade 4 hematological or any
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::820e1c8674f7a8df8bced6fca976a544
https://doi.org/10.1007/s10147-012-0410-z
https://doi.org/10.1007/s10147-012-0410-z
Autor:
Arben Lleshi, Umberto Tirelli, N. Meneguzzo, Francesco Fiorica, Alessandro Cocciolo, Massimiliano Berretta, Guglielmo Nasti, Alessandro Cappellani, Alessandra Bearz, Renato Talamini, Antonio Bolognese, Maurizio Ristagno, Rosa Tambaro, R Fisichella, Sergio Frustaci, Salvatore Berretta, Francesco Basile
Publikováno v:
Archives of Gerontology and Geriatrics. 52:89-93
Elderly patients constitute a subpopulation with special characteristics that differ from those of the general population and have been under-represented in clinical trials. We, prospectively, analyzed the toxicity and efficacy of the original FOLFOX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ba2e08c306b697135ec8467a914853f
https://doi.org/10.1016/j.archger.2010.02.006
https://doi.org/10.1016/j.archger.2010.02.006
Autor:
Antonella Boglione, Silvia Stacchiotti, Emanuela Palmerini, Massimo Aglietta, Giovanni Grignani, Alessandro Comandone, Stefano Ferrari, Sergio Frustaci, Paolo G. Casali, Virginia Ferraresi
Publikováno v:
Cancer. 117:826-831
BACKGROUND. Chondrosarcoma (CS) is a rare and heterogeneous sarcoma in which, after failure of surgery and radiotherapy, chemotherapy plays only a marginal role. Different molecular pathways have been shown to be activated in CS; in particular, both
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::906432a34dc76e60f2354889e7c864e0
https://doi.org/10.1002/cncr.25632
https://doi.org/10.1002/cncr.25632
Autor:
Angela Buonadonna, Mario D'Andrea, Erika Cecchin, Mauro Giusto, Massimo Boccalon, Antonio Russo, Fernando Gaion, Giuseppe Toffoli, Salvatore Bonura, Paolo Sandri, Enzo Galligioni, Vincenzo De Pangher, Sergio Pessa, Michele Medici, Domenico Errante, Paola Biason, Lara Maria Pasetto, Sergio Frustaci, Giuseppe Corona
Publikováno v:
Journal of Clinical Oncology. 24:3061-3068
PurposeUGT1A1*28 polymorphism has been associated with decreased glucuronidation of SN38, the active metabolite of irinotecan. This could increase toxicity with this agent.Patients and MethodsIn a prospective study, 250 metastatic colorectal cancer p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5de648a2379ff2345e3af769fc2a92db
https://doi.org/10.1200/jco.2005.05.5400
https://doi.org/10.1200/jco.2005.05.5400
Autor:
Sergio Frustaci, R Taibi, N. La Mura, Umberto Tirelli, Alessandra Bearz, Salvatore Berretta, Massimiliano Berretta
Publikováno v:
Scopus-Elsevier
Oxaliplatin is a new, third-generation platinum complex. It has a good safety profile characterized by low hematological-gastrointestinal toxicity. No significant nephro-ototoxicity has been observed. Acute peripheral neuropathy is a common event aff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0f5d5915fefe49da1b7206a85756b4a
https://doi.org/10.1179/joc.2004.16.6.595
https://doi.org/10.1179/joc.2004.16.6.595
Autor:
A. De Paoli, Angela Buonadonna, Sergio Frustaci, Ettore Bidoli, Giovanni Boz, Massimiliano Berretta, Franco Gherlinzoni, N. La Mura
Publikováno v:
Oncology. 65:80-84
Ifosfamide and anthracyclines are the only active agents in advanced soft tissue sarcomas. Doxorubicin was always used in sarcomas, whereas ifosfamide was reintroduced in the clinic after the discovery of mesna which prevents its typical dose-limitin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81be57d71cf0b527ebe70a4cc763c04e
https://doi.org/10.1159/000073366
https://doi.org/10.1159/000073366
Autor:
Francesco Oniga, Fausto Barbieri, Giovanni Luca Ceresoli, Adolfo Favaretto, Adriano Paccagnella, C. Ghiotto, S. Schiavon, Alessandra Bearz, E. Villa, Sergio Frustaci
Publikováno v:
Scopus-Elsevier
Summary Background: The combination of paclitaxel (P) and carboplatin (C) is an effective treatment for advanced NSCLC. Gemcitabine (G) is an active new drug. We planned a phase I study to find the maximum tolerated dose (MTD) of the PCG combination.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faa5391c291a1400c4e1c53394f90c32
https://doi.org/10.1023/a:1026527004596
https://doi.org/10.1023/a:1026527004596